Given the exciting applications of CRISPR in fields ranging from gene therapy to genetically modified foods, there has naturally been intense scrutiny of the ongoing dispute regarding the discovery and patenting of CRISPR gene editing technology. No one has covered this story more intensively or adeptly than Professor Jacob Sherkow, an academic law professor at New York Law School. In this interview conducted by Dr. Kevin Davies (Executive Editor, The CRISPR Journal), Professor Sherkow provides a brief accessible history of the ongoing CRISPR patent dispute, discussing the implications as well as other legal issues, impacting the world of biotechnology. (This is a lightly edited version of the conversation, which was held on March 20, 2018.).
ASJC Scopus subject areas
- Management, Monitoring, Policy and Law